Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    • News

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

  • BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    • News

  • Harris Technology eyes profitability as refurbished tech sales surge
    Harris Technology eyes profitability as refurbished tech sales surge
    • News

  • QIC Fund Backs Ark Mines with $4.5m to Accelerate Sandy Mitchell Development
    • News

  • Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    • News

  • FBR’s tech could help reduce housing construction-related cost pressures
    FBR’s tech could help reduce housing construction-related cost pressures
    • News

  • Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    • News

MyFiziq inks Tinjoy deal to access 28 million new customers in China

  • In News
  • February 18, 2021
  • Alfred Chan
MyFiziq inks Tinjoy deal to access 28 million new customers in China

Health tech company MyFiziq (ASX: MYQ) is making rapid inroads into the lucrative health-conscious Chinese market having signed terms with Tinjoy Biotech to secure direct access to their 28 million consumers.

The deal will see MyFiziq’s CompleteScan app integrated with Tinjoy’s WinScan Digital Health Platform where MyFiziq will utilise Tinjoy’s call centre of almost 1,000 telemarketers to contact WinScan users to buy MyFiziq products within the WinScan platform.

“Tinjoy has developed a tailored approach to better health outcomes and engagement in corporate, community and telehealth platform,” said MyFiziq CEO, Vlado Bosanac.

“I am also pleased Tinjoy views the agreement as a long-term partnership with their openness to MyFiziq acquiring a substantive holding if the platform achieves monthly users of 5,000,000 or more.

“The agreed consideration would be well under the monthly revenue MyFiziq would see based on the pricing we have structured in consultation with Tinjoy”.

The WinScan platform is just one of Tinjoy’s products with the Company’s primary operations focusing on traditional Chinese medicines based in the Guangdong Province. Through this pharmaceuticals business, Tinjoy has been able to establish a mass customer base where they achieve ongoing relationships with their customers through WinScan to promote ongoing health consciousness.

“MyFiziq has the potential to redefine not only the marketplace but also people’s relationship with their own health,” said Tinjoy Executive Director, Russell Bateman.

“The CompleteScan offering will be a valuable part of our user experience and engagement. We service millions of customers each month via our pharmacies and call centre marketing initiatives.

“China is a unique market and navigating the language is somewhat difficult. The reason our digital platform is so successful is we are able to deliver our customers a seamless easy to follow framework via our WeChat application. Our intention is to offer the CompleteScan functions as individual tests to draw people to their specific need case.”

As part of the deal, MyFiziq will fund USD $100,000 towards training of call centre staff while Tinjoy will commission bonuses for staff that can achieve elite sales targets and drive uptake towards the targetted 1,000,000 monthly users of MyFiziq products.

For the quarter ending 31 December 2020, MyFiziq reported cash receipts of AUD $456k but $847k negative cash flow. Despite this, investors have been flocking to MyFiziq which has a clear focus on partnerships to drive revenues now that their tech has reached commercialisation with MYQ shares having risen from $0.30 in July 2020 to now be trading around $1.80.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
  •  
  •  
  •  
  •  
  • asx myq
  • health tech
  • healthcare
  • medtech
  • MyFiziq
  • MYQ
  • russell bateman
  • tinjoy
  • vlado bosanac
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.